Cart
sales@molnova.com
Exatecan Mesylate
CAS No. 169869-90-3
Exatecan Mesylate( DX8951f )
Catalog No. M22421 CAS No. 169869-90-3
Exatecan Mesylate is a DNA topoisomerase I inhibitor (IC50: 2.2 μM, 0.975 μg/mL).Exatecan Mesylate (DX-8951f) significantly inhibits the proliferation of several cancer cell lines, with mean GI50s of 2.02 ng/mL, 2.92 ng/mL, 1.53 ng/mL, and 0.877 ng/mL for breast cancer cells, colon cancer cells, stomach cancer cells and lung cancer cells, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 10MG | 29 | In Stock |
|
| 25MG | 61 | In Stock |
|
| 50MG | 86 | In Stock |
|
| 100MG | 129 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 276 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameExatecan Mesylate
-
NoteResearch use only, not for human use.
-
Brief DescriptionExatecan Mesylate is a DNA topoisomerase I inhibitor (IC50: 2.2 μM, 0.975 μg/mL).Exatecan Mesylate (DX-8951f) significantly inhibits the proliferation of several cancer cell lines, with mean GI50s of 2.02 ng/mL, 2.92 ng/mL, 1.53 ng/mL, and 0.877 ng/mL for breast cancer cells, colon cancer cells, stomach cancer cells and lung cancer cells, respectively.
-
DescriptionExatecan Mesylate is a DNA topoisomerase I inhibitor (IC50: 2.2 μM, 0.975 μg/mL).Exatecan Mesylate (DX-8951f) significantly inhibits the proliferation of several cancer cell lines, with mean GI50s of 2.02 ng/mL, 2.92 ng/mL, 1.53 ng/mL, and 0.877 ng/mL for breast cancer cells, colon cancer cells, stomach cancer cells and lung cancer cells, respectively. Exatecan displays cytotoxic activities against PC-6, PC-6/SN2-5 cells, with mean GI50s of 0.186 and 0.395 ng/mL, respectively. Exatecan Mesylate (34 nM) stabilizes DNA-TopoI complexes in PC-6 and PC-6/SN2-5 cells.Exatecan Mesylate (3.325-50 mg/kg, i.v.) exhibits antitumor activities in the mice model bearing tumor cells, without toxic death. Exatecan Mesylate (15, 25 mg/kg, i.v.) highly inhibits MIA-PaCa, BxPC-3 primary tumor growth in the MIA-PaCa-2 early-stage model and early-stage model of BxPC-3. Exatecan Mesylate (15, 25 mg/kg, i.v.) also significantly suppresses BxPC-3 lymphatic metastasis and completely eliminates lung metastasis in the BxPC-3 late-stage cancer model.
-
In Vitro——
-
In Vivo——
-
SynonymsDX8951f
-
PathwayCell Cycle/DNA Damage
-
TargetTopoisomerase
-
RecptorTopo I
-
Research AreaCancer
-
IndicationBiliary cancer; Breast cancer; Cervical cancer; Ewing's sarcoma; Gastric cancer; Haematological malignancies; Liver cancer; Myelodysplastic syndromes; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Rhabdomyosarcoma; Solid tumours
Chemical Information
-
CAS Number169869-90-3
-
Formula Weight531.55
-
Molecular FormulaC25H26FN3O7S
-
Purity>98% (HPLC)
-
SolubilityDMSO:8 mg/mL (15.05 mM; Need ultrasonic);Water:6 mg/mL (11.29 mM; Need ultrasonic and warming)
-
SMILESCS(O)(=O)=O.CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Mitsui I, et al. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Jpn J Cancer Res. 1995 Aug;86(8):776-82.
molnova catalog
related products
-
Amonafide
A novel topoisomerase II (Topo II) inhibitor and DNA intercalator that induces apoptotic signaling by blocking the binding of Topo II to DNA.
-
ARN-21934
ARN-21934 is a potent and selective inhibitor for human topoisomerase II α and topoisomerase II β. ARN-21934(IC50 = 2 μM) inhibits DNA relaxation as compared to the anticancer agent Etoposide (IC50=120 μM).
-
Amsacrine hydrochlor...
Amsacrine?hydrochloride? is topoisomerase II inhibitor is used in the treatment of acute myelogenous leukemia.?
